Pierre Morissette
Overview
Explore the profile of Pierre Morissette including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
170
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Regan C, Morissette P, Kraus R, Wang E, Arrington L, Vavrek M, et al.
Circulation
. 2024 Apr;
149(17):1394-1396.
PMID: 38648272
No abstract available.
2.
Adams G, Pall P, Grauer S, Zhou X, Ballard J, Vavrek M, et al.
J Med Chem
. 2021 Dec;
65(1):485-496.
PMID: 34931831
Inhibitor cystine knot peptides, derived from venom, have evolved to block ion channel function but are often toxic when dosed at pharmacologically relevant levels . The article describes the design...
3.
Morissette P, Li N, Ballard J, Vavrek M, Adams G, Regan C, et al.
Toxicol Sci
. 2021 Dec;
185(2):170-183.
PMID: 34897513
Studies have shown that some peptides and small molecules can induce non IgE-mediated anaphylactoid reactions through mast cell activation. Upon activation, mast cells degranulate and release vasoactive and proinflammatory mediators,...
4.
Morissette P, Polak S, Chain A, Zhai J, Imredy J, Wildey M, et al.
Toxicol Appl Pharmacol
. 2020 Jan;
390:114883.
PMID: 31981640
Human-based in silico models are emerging as important tools to study the effects of integrating inward and outward ion channel currents to predict clinical proarrhythmic risk. The aims of this...
5.
Li Z, Mirams G, Yoshinaga T, Ridder B, Han X, Chen J, et al.
Clin Pharmacol Ther
. 2019 Nov;
107(1):102-111.
PMID: 31709525
This white paper presents principles for validating proarrhythmia risk prediction models for regulatory use as discussed at the In Silico Breakout Session of a Cardiac Safety Research Consortium/Health and Environmental...
6.
Passini E, Trovato C, Morissette P, Sannajust F, Bueno-Orovio A, Rodriguez B
Br J Pharmacol
. 2019 Jul;
176(19):3819-3833.
PMID: 31271649
Background And Purpose: Early identification of drug-induced cardiac adverse events is key in drug development. Human-based computer models are emerging as an effective approach, complementary to in vitro and animal...
7.
Dong S, VanGelder K, Shi Z, Yu Y, Wu Z, Ferguson R, et al.
Bioorg Med Chem Lett
. 2017 Apr;
27(11):2559-2566.
PMID: 28431879
SAR in the previously described spirocyclic ROMK inhibitor series was further evolved from lead 4 by modification of the spirocyclic core and identification of novel right-side pharmacophores. In this process,...
8.
Lagrutta A, Regan C, Zeng H, Imredy J, Koeplinger K, Morissette P, et al.
Sci Rep
. 2017 Mar;
7:44820.
PMID: 28327633
Severe bradycardia/bradyarrhythmia following coadministration of the HCV-NS5B prodrug sofosbuvir with amiodarone was recently reported. Our previous preclinical in vivo experiments demonstrated that only certain HCV-NS5B prodrugs elicit bradycardia when combined...
9.
Gotta V, Yu Z, Cools F, Van Ammel K, Gallacher D, Visser S, et al.
Pharmacol Res Perspect
. 2017 Jan;
4(6):e00270.
PMID: 28097003
Drug-induced QTc interval prolongation ( QTc) is a main surrogate for proarrhythmic risk assessment. A higher in vivo than in vitro potency for hERG-mediated QTc prolongation has been suggested. Also,...
10.
Wolfrom B, Hodgetts G, Kotecha J, Pollock E, Martin M, Han H, et al.
Can Fam Physician
. 2016 Sep;
62(9):e540-6.
PMID: 27629689
Objective: To evaluate satisfaction with civilian residency training programs among serving general duty medical officers within the Canadian Armed Forces. Design: A 23-item, cross-sectional survey face-validated by the office of...